HERG Screening Market Share, Size, Trends, Industry Analysis Report, By Product Type (Gene KCNH2, Mutant KCNH2, Others); By Ion Channel; By Application; By Region; Segment Forecast, 2024 - 2032

HERG Screening Market Share, Size, Trends, Industry Analysis Report, By Product Type (Gene KCNH2, Mutant KCNH2, Others); By Ion Channel; By Application; By Region; Segment Forecast, 2024 - 2032

The global HERG screening market size is expected to reach USD 6.10 million by 2032, according to a new study by Polaris Market Research. The report “HERG Screening Market Share, Size, Trends, Industry Analysis Report, By Product Type (Gene KCNH2, Mutant KCNH2, Others); By Ion Channel; By Application; By Region; Segment Forecast, 2024-2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Market is being driven by the increasing number of innovative medication approvals and the rising prevalence of cardiac disorders. In 2019, 9.6 Mn men & 8.9 Mn women died from the cardiovascular diseases across the globe, with further than 6 Mn of them aged 30-70. Such deaths were majorly from India, Russia, China, United States, & Indonesia. Nonetheless, unexplored markets are anticipated to create a lucrative potential for this market's growth soon.

Rise in the incidence of heart illnesses and the number of people suffering from heart ailments are likely to drive market growth. Furthermore, a rise in the approvals of novel drug entities along with in silico techniques is projected to contribute in market expansion. For instance, machine learning based algorithmic models have been developed to screen the DrugBank database for the potential hERG blockers. To create cutting-edge machine learning models, were combined with gradient boosting tree & deep-rooted neural algorithms.

In recent years, researchers have concentrated on avoiding the hyper-activity of the hERG K+ channel while at the same time testing novel drugs for the pro-arrhythmic potential, as hERG block is a common characteristic of the many pro-arrhythmic substances linked with the “Torsades de Pointes” in people.

The rising prevalence of cardiac disease and medicine development to treat it may enhance the use of HERG screening tools. Furthermore, the drop in price to more reasonable levels may assist to increase the use of HERG screening kits.

There were no precise diagnostic tests available to detect COVID-19 in patients during the early stages of the epidemic. Because COVID-19 diagnostic tests were unavailable, diagnostic manufacturers saw profitable chances to create COVID-19 diagnostic kits. These firms gained an advantage over other diagnostics players by leveraging on demand for COVID-19 diagnostic tests, which enables them sustain revenues in such a situation. Fast C-type inactivation provides specific functional features to the hERG potassium channel, and its relationship with inherited and acquired cardiac arrhythmias makes atomic-level hERG inactivation mechanism research critical.

HERG Screening market Report Highlights

The KCNH2 gene is part of a wide family of genes that code for potassium channel instructions and a KCNH2 mutation causes cardiac arrhythmia, hence share a significant hold in the market share.

Voltage gated ion channels dominated the worldwide market, along with the fastest-growing sector which is ion gated channels.

The antiarrhythmic medication application sector is expected to account for a sizable market share as it modifies the functional activity of the ion channel.

North America accounted for the largest revenue share primarily due presence of key companies & awareness among individuals

The global players include Abcam PLC, PerkinElmer Company, ABR-Affinity Bioreagents, AstraZeneca, Aureus Sciences, Aurora Sciences, AVIVA Biosciences, B’SyS GmbH, Caliper, Fujifilm Cellular Dynamics, Cambridge Biosciences, ChanTest Corporation, Charles River Laboratories, ChemAxon, Eurofins-Cerep, and Molecular Devices.

Polaris Market Research has segmented the HERG screening market report based on product type, ion channel, application, and region:

HERG Screening, Product Type Outlook (Revenue - USD Million, 2019 - 2032)

Gene KCNH2

Mutant KCNH2

Others

HERG Screening, Ion Channel Outlook (Revenue - USD Million, 2019 - 2032)

Voltage Gated

Ligand Gated

Others

HERG Screening, Application Outlook (Revenue - USD Million, 2019 - 2032)

Antiarrhythmic

Antipsychotic

Antibiotic

Others

HERG Screening, Regional Outlook (Revenue - USD Million, 2019 - 2032)

North America

U.S.

Canada

Europe

Germany

UK

France

Italy

Spain

Russia

Netherlands

Asia Pacific

China

India

Japan

South Korea

Indonesia

Malaysia

Latin America

Argentina

Brazil

Mexico

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa